Literature DB >> 12552200

Interaction of isoflurane with the dopamine transporter.

John Votaw1, Michael Byas-Smith, Jian Hua, Ronald Voll, Laurent Martarello, Allan I Levey, F DuBois Bowman, Mark Goodman.   

Abstract

BACKGROUND: Isoflurane administration is known to increase extracellular dopamine (DA) concentration. Because the dopamine transporter (DAT) is a key regulator of DA, it is likely affected by isoflurane. This study investigates the hypothesis that isoflurane inhibits DA reuptake by causing DAT to be trafficked into the cell.
METHODS: Rhesus monkeys were scanned with positron emission tomography (PET) using [18F]FECNT (a highly specific DAT ligand) while anesthetized with 1% isoflurane. The isoflurane was increased to 2%, and the animals were rescanned. Uptake was analyzed with the tissue reference method using the cerebellum as the reference tissue to determine the binding potential in the putamen. Immunohistochemistry and Western blot analyses were performed in rats to determine if isoflurane administration would change the total amount of DAT. Rats breathed air plus 2% isoflurane for 30 min, and then striatal DAT assays were rapidly performed. immunocytochemistry experiments were performed using human embryonic kidney (HEK) cells stably transfected with human DAT. The cells were exposed to 4% isoflurane for 1 h while the location of DAT was observed with fluorescent confocal microscopy.
RESULTS: The [18F]FECNT binding potential in rhesus monkeys decreased by 63 +/- 6% (SEM, n = 5) when isoflurane was increased from 1 to 2% as compared with no significant change (0.7 +/- 2.5%; SEM, n = 5) when the isoflurane concentration was not changed (P < 0.001). No difference in DAT staining between isoflurane-treated and control rats was apparent from visual inspection, and quantitative Western blot analyses showed no significant change in total DAT protein. After isoflurane treatment, focal puncta of intense fluorescence was visible inside the HEK cells.
CONCLUSIONS: The experiments indicate that DAT is trafficked into the cell by isoflurane without changing the total amount of DAT in the striatum. The PET data are consistent with this finding, provided that intracellular DAT acquires a conformation that has low affinity for [18F]FECNT. Thus, [18F]FECNT appears to be an excellent agent for measuring plasma membrane-expressed DAT and evaluating DAT trafficking.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552200     DOI: 10.1097/00000542-200302000-00021

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  20 in total

1.  Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.

Authors:  Robert H Mach; Zhude Tu; Jinbin Xu; Shihong Li; Lynne A Jones; Michelle Taylor; Robert R Luedtke; Colin P Derdeyn; Joel S Perlmutter; Mark A Mintun
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

2.  Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Vernon M Camp; Eugene J Malveaux; John R Votaw; Leonard Howell; Michael J Owens; Mark M Goodman
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 3.  Neurochemical modulators of sleep and anesthetic states.

Authors:  Christa J Van Dort; Helen A Baghdoyan; Ralph Lydic
Journal:  Int Anesthesiol Clin       Date:  2008

4.  Sex differences in effects of dopamine D1 receptors on social withdrawal.

Authors:  Katharine L Campi; Gian D Greenberg; Amita Kapoor; Toni E Ziegler; Brian C Trainor
Journal:  Neuropharmacology       Date:  2013-10-10       Impact factor: 5.250

5.  Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Lauryn M Daniel; Ping Chen; Ronald J Voll; Larry Williams; Susan J Plott; John R Votaw; Michael J Owens; Leonard Howell; Mark M Goodman
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

6.  Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Authors:  Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2015-06-19       Impact factor: 3.641

7.  Effect of Animal Condition and Fluvoxamine on the Result of [(18)F]N-3-Fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) Nortropane ([(18)F]FP-CIT) PET Study in Mice.

Authors:  Kwang-Ho Shin; Su-A Park; Seog-Young Kim; Sang Ju Lee; Seung Jun Oh; Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-11-26

8.  The effect of anaesthesia on [(18)F]MK-9470 binding to the type 1 cannabinoid receptor in the rat brain.

Authors:  Cindy Casteels; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

9.  Dopamine uptake dynamics are preserved under isoflurane anesthesia.

Authors:  Zachary D Brodnik; Rodrigo A España
Journal:  Neurosci Lett       Date:  2015-08-28       Impact factor: 3.046

10.  [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot.

Authors:  Mohammed N Tantawy; Carrie K Jones; Ronald M Baldwin; M Sib Ansari; P Jeffrey Conn; Robert M Kessler; Todd E Peterson
Journal:  Nucl Med Biol       Date:  2009-10-03       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.